デフォルト表紙
市場調査レポート
商品コード
1462295

FDY-5301の市場規模、予測、新薬の考察(2032年)

FDY-5301 Market Size, Forecast, and Emerging Insight - 2032

出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 30 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
FDY-5301の市場規模、予測、新薬の考察(2032年)
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

薬剤のサマリー

FDY-5301はヨウ化ナトリウムを含む元素還元剤であり、Faradayは世界の主要市場において使用方法の特許を取得しています。FDY-5301の前臨床試験では、心筋と骨格筋の傷害を軽減する能力が実証されています。フェーズI試験では、健常者に毒性は認められませんでした。STEMI後の再灌流障害の治療におけるFDY-5301のフェーズII試験では、この治療が良好な忍容性を示し、心臓障害を最小化する潜在的な有効性の有望な兆候が示されました。

2022年5月、Faraday PharmaceuticalsはIocyte AMI-III試験(一次経皮的インターベンション(PCI)を受ける前STEMI患者のCV死と心不全の減少におけるFDY-5301の有効性と安全性を評価するフェーズ3臨床試験)の最初の患者を登録しました。本試験は北米、欧州、イスラエルの150施設全体で約2,300人の前STEMI患者の登録を目指しています。この試験は米国FDAとの特別プロトコル契約に基づき実施されます。本試験が成功すれば、上市承認申請の支えとなる可能性があります。

当レポートでは、主要7市場(米国・ドイツ・フランス・イタリア・スペイン・英国・日本)における心筋梗塞向けFDY-5301について調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 心筋梗塞におけるFDY-5301の概要

  • 製品の詳細
  • 臨床開発
    • 臨床研究
    • 臨床試験情報
    • 安全性と有効性
  • その他の開発活動
  • 製品プロファイル

第3章 競合情勢(上市済みの治療法)

第4章 競合情勢(後期の新治療法)

第5章 FDY-5301市場の評価

  • 心筋梗塞におけるFDY-5301の市場見通し
  • 主要7市場の分析
    • 主要7市場の心筋梗塞向けFDY-5301の市場規模
  • 市場の分析:国別
    • 米国の心筋梗塞向けFDY-5301の市場規模
    • ドイツの心筋梗塞向けFDY-5301の市場規模
    • 英国の心筋梗塞向けFDY-5301の市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

図表

List of Tables

  • Table 1: FDY-5301, Clinical Trial Description, 2023
  • Table 2: FDY-5301, General Description
  • Table 3: Competitive Landscape (Marketed Therapies)
  • Table 4: Competitive Landscape (Late-stage Emerging Therapies)
  • Table 5: FDY-5301 Market Size in the 7MM, in USD million (2019-2032)
  • Table 6: FDY-5301 Market Size in the US, in USD million (2019-2032)
  • Table 7: FDY-5301 Market Size in Germany, in USD million (2019-2032)
  • Table 8: FDY-5301 Market Size in France, in USD million (2019-2032)
  • Table 9: FDY-5301 Market Size in Italy, in USD million (2019-2032)
  • Table 10: FDY-5301 Market Size in Spain, in USD million (2019-2032)
  • Table 11: FDY-5301 Market Size in the UK, in USD million (2019-2032)
  • Table 12: FDY-5301 Market Size in Japan, in USD million (2019-2032)

List of Figures

  • Figure 1: FDY-5301 Market Size in the 7MM, USD million (2019-2032)
  • Figure 2: FDY-5301 Market Size in the United States, USD million (2019-2032)
  • Figure 3: FDY-5301 Market Size in Germany, USD million (2019-2032)
  • Figure 4: FDY-5301 Market Size in France, USD million (2019-2032)
  • Figure 5: FDY-5301 Market Size in Italy, USD million (2019-2032)
  • Figure 6: FDY-5301 Market Size in Spain, USD million (2019-2032)
  • Figure 7: FDY-5301 Market Size in the United Kingdom, USD million (2019-2032)
  • Figure 8: FDY-5301 Market Size in Japan, USD million (2019-2032)
目次
Product Code: DIDM1234

"FDY-5301 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about FDY-5301 for myocardial infarction in the seven major markets. A detailed picture of the FDY-5301 for myocardial infarction in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the FDY-5301 for myocardial infarction. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the FDY-5301 market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.

Drug Summary:

FDY-5301 is an elemental reducing agent containing sodium iodide for which Faraday has obtained a method of use patent protection in major markets worldwide. Preclinical studies of FDY-5301 have demonstrated its ability to reduce cardiac and skeletal muscle injury. Phase I data have demonstrated no signs of toxicity in healthy subjects. A Phase II trial of FDY-5301 in treating reperfusion injury following a STEMI demonstrated the treatment was well-tolerated and provided encouraging signals of potential efficacy in minimizing cardiac damage.

In May 2022, Faraday Pharmaceuticals enrolled the first patient in its Iocyte AMI-III study - a Phase III clinical trial assessing the efficacy and safety of FDY-5301 in reducing CV death and heart failure in anterior STEMI patients undergoing primary percutaneous intervention (PCI). The study aims to enroll approximately 2,300 anterior STEMI patients across 150 centers in North America, Europe, and Israel. The trial is being conducted under a special protocol agreement with the US FDA. The study, if successful, would support a regulatory submission for marketing approval.

Scope of the Report:

The report provides insights into:

  • A comprehensive product overview including the FDY-5301 description, mechanism of action, dosage and administration, research and development activities in myocardial infarction.
  • Elaborated details on FDY-5301 regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the FDY-5301 research and development activities in myocardial infarction across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around FDY-5301.
  • The report contains forecasted sales of FDY-5301 for myocardial infarction till 2032.
  • Comprehensive coverage of the late-stage emerging therapies for myocardial infarction.
  • The report also features the SWOT analysis with analyst views for FDY-5301 in myocardial infarction.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

FDY-5301 Analytical Perspective by DelveInsight

  • In-depth FDY-5301 Market Assessment

This report provides a detailed market assessment of FDY-5301 for myocardial infarction in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

  • FDY-5301 Clinical Assessment

The report provides the clinical trials information of FDY-5301 for myocardial infarction covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

  • In the coming years, the market scenario for myocardial infarction is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence FDY-5301 dominance.
  • Other emerging products for myocardial infarction are expected to give tough market competition to FDY-5301 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of FDY-5301 in myocardial infarction.
  • Our in-depth analysis of the forecasted sales data of FDY-5301 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FDY-5301 in myocardial infarction.

Key Questions:

  • What is the product type, route of administration and mechanism of action of FDY-5301?
  • What is the clinical trial status of the study related to FDY-5301 in myocardial infarction and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the FDY-5301 development?
  • What are the key designations that have been granted to FDY-5301 for myocardial infarction?
  • What is the forecasted market scenario of FDY-5301 for myocardial infarction?
  • What are the forecasted sales of FDY-5301 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how are these giving competition to FDY-5301 for myocardial infarction?
  • Which are the late-stage emerging therapies under development for the treatment of myocardial infarction?

Table of Contents

1. Report Introduction

2. FDY-5301 Overview in myocardial infarction

  • 2.1. Product Detail
  • 2.2. Clinical Development
    • 2.2.1. Clinical studies
    • 2.2.2. Clinical trials information
    • 2.2.3. Safety and efficacy
  • 2.3. Other Developmental Activities
  • 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. FDY-5301 Market Assessment

  • 5.1. Market Outlook of FDY-5301 in myocardial infarction
  • 5.2. 7MM Analysis
    • 5.2.1. Market Size of FDY-5301 in the 7MM for myocardial infarction
  • 5.3. Country-wise Market Analysis
    • 5.3.1. Market Size of FDY-5301 in the United States for myocardial infarction
    • 5.3.2. Market Size of FDY-5301 in Germany for myocardial infarction
    • 5.3.3. Market Size of FDY-5301 in France for myocardial infarction
    • 5.3.4. Market Size of FDY-5301 in Italy for myocardial infarction
    • 5.3.5. Market Size of FDY-5301 in Spain for myocardial infarction
    • 5.3.6. Market Size of FDY-5301 in the United Kingdom for myocardial infarction
    • 5.3.7. Market Size of FDY-5301 in Japan for myocardial infarction

6. SWOT Analysis

7. Analysts' Views

8. Appendix

  • 8.1. Bibliography
  • 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options